Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema

MJ Elman, LP Aiello, RW Beck, NM Bressler… - Ophthalmology, 2010 - Elsevier
OBJECTIVE: Evaluate intravitreal 0.5 mg ranibizumab or 4 mg triamcinolone combined with
focal/grid laser compared with focal/grid laser alone for treatment of diabetic macular edema …
被引用次数：1839 相关文章

Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema.

MJ Elman, LP Aiello, RW Beck, NM Bressler… - …, 2010 - europepmc.org
Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus
prompt laser for diabetic macular edema. - Abstract - Europe PMC Sign in | Create an account …
[PDF] ophed.net

[PDF][PDF] Randomized Trial Evaluating Ranibizumab Plus Prompt or Deferred Laser or Triamcinolone Plus Prompt Laser for Diabetic Macular Edema

MD Bressler, SB Bressler, AR Edwards, FL Ferris III… - Ophthalmology, 2010 - ophed.net
Objective: Evaluate intravitreal 0.5 mg ranibizumab or 4 mg triamcinolone combined with
focal/grid laser compared with focal/grid laser alone for treatment of diabetic macular edema …

Randomized Trial Evaluating Ranibizumab Plus Prompt or Deferred Laser or Triamcinolone Plus Prompt Laser for Diabetic Macular Edema

MJ Elman, LP Aiello, RW Beck, NM Bressler… - …, 2010 - aaojournal.org
Objective Evaluate intravitreal 0.5 mg ranibizumab or 4 mg triamcinolone combined with
focal/grid laser compared with focal/grid laser alone for treatment of diabetic macular edema …

Randomized Trial Evaluating Ranibizumab Plus Prompt or Deferred Laser or Triamcinolone Plus Prompt Laser for Diabetic Macular Edema

MJ Elman, LP Aiello, RW Beck, NM Bressler… - Ophthalmology, 2010 - infona.pl
Evaluate intravitreal 0.5 mg ranibizumab or 4 mg triamcinolone combined with focal/grid
laser compared with focal/grid laser alone for treatment of diabetic macular edema (DME) …

Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema

MJ Elman, LP Aiello, RW Beck, NM Bressler… - 2010 - pubmed.ncbi.nlm.nih.gov
Objective Evaluate intravitreal 0.5 mg ranibizumab or 4 mg triamcinolone combined with
focal/grid laser compared with focal/grid laser alone for treatment of diabetic macular edema …
[PDF] ophed.com

[PDF][PDF] Randomized Trial Evaluating Ranibizumab Plus Prompt or Deferred Laser or Triamcinolone Plus Prompt Laser for Diabetic Macular Edema

MD Bressler, SB Bressler, AR Edwards, FL Ferris III… - Ophthalmology, 2010 - ophed.com
Objective: Evaluate intravitreal 0.5 mg ranibizumab or 4 mg triamcinolone combined with
focal/grid laser compared with focal/grid laser alone for treatment of diabetic macular edema …

Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema

P EDWARDS - Acta Ophthalmologica, 2010 - Wiley Online Library
Purpose To evaluate the safety and efficacy of intravitreal ranibizumab combined with
prompt or deferred laser or intravitreal triamcinolone combined with prompt laser compared …

Randomized Trial Evaluating Ranibizumab Plus Prompt or Deferred Laser or Triamcinolone Plus Prompt Laser for Diabetic Macular Edema

MJ Elman, LP Aiello, RW Beck, NM Bressler… - Ophthalmology, 2010 - Elsevier
Objective Evaluate intravitreal 0.5 mg ranibizumab or 4 mg triamcinolone combined with
focal/grid laser compared with focal/grid laser alone for treatment of diabetic macular edema …
[HTML] nih.gov

[HTML][HTML] Randomized Trial Evaluating Ranibizumab Plus Prompt or Deferred Laser or Triamcinolone Plus Prompt Laser for Diabetic Macular Edema

MJ Elman, LP Aiello, RW Beck, NM Bressler… - …, 2010 - ncbi.nlm.nih.gov
Randomized Trial Evaluating Ranibizumab Plus Prompt or Deferred Laser or Triamcinolone
Plus Prompt Laser for Diabetic Macular Edema - PMC Back to Top Skip to main content NIH …